© Copyright 2026, All Rights Reserved
Develop bispecific ADCs for treating CRC; Advance oncology programs for NSCLC; Create drugs targeting pan-cancer indications; Minimize side effects in cancer therapies; Explore new payloads for drug delivery
Closed $11.8 million Pre-A financing round; Appointed biopharmaceutical veteran Martin D. Williams as Chair; Presentations at major industry events; Active pipeline with multiple oncology programs